TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Teladoc Health, Inc. (TDOC)

Healthcare Health Information Services
6.70 $
+2.0% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

symbol.quality_heading

Open questions

The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.

Yellow because a material operating question is open, not because the substance is failing. The business pays its own way in cash ($294.4 million of operating cash flow in 2025, a 47.6 percent equity ratio as of July 28, 2026, no maturity before June 2027 and an undrawn revolver), and the $1,000.0 million of convertible notes can be covered on paper from cash, ongoing cash flow and the $300.0 million facility — the documented substance finding that red would require is absent. What is missing for green is proof that the revenue decline ends in 2026 and that BetterHelp turns its user curve: paying users down 9 percent, U.S. membership down 1.3 million and segment profit down from $7.7 million to $1.9 million in the first quarter of 2026 describe an open turnaround, not a proven one. That the stock looks cheap on revenue changes nothing here — price is not a quality attribute. The decision is yours.

symbol.quality_note

Read the Full Deep Dive
Teladoc Health: 101 Million Members, $2.5 Billion in Revenue — and $14.3 Billion of Goodwill That Was Never There

Teladoc Health is the largest virtual care company in the world: 101.2 million U.S. members as of March 31, 2026, 17.1 million visits in 2025 alone, roughly 5,600 employees and $2,530.0 million of revenue. The business pays its own way in cash — $294.4 million of operating cash flow in 2025. And yet the same filings with the U.S. securities regulator, the SEC, disclose $14.3 billion of goodwill already written off, every acquisition inside the Integrated Care segment impaired on the day it closed, and $1.0 billion of convertible notes falling due on June 1, 2027 — against $750.7 million of cash. Not investment advice — just the question of what a dollar of revenue is worth after $14.3 billion of it was once paid for by mistake.

Read the analysis

Stock Watch

This analysis is as of July 29, 2026. Stock Watch will tell you what's changed at TDOC since then.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 2 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
6.60$
Open
6.50$
Day High
6.80$
Day Low
6.40$
Volume
8,550,546shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
4.50 $ 9.70 $
02/12/2026 07/15/2026

Current price 6.70 $ — 42% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
1.2$B
Shares Outstanding
182Mio.
Float
99.4%
Beta
2.1

Performance

Perf. 1M
15.70%
Perf. 3M
69.10%
Perf. 6M
19.90%
YTD Performance (%)
9.90%
52-Week-High Distance
-19.0%
Perf. 1Y
-6.93%
Perf. 3Y
-77.46%
Perf. 5Y
-95.48%
Perf. 10Y
-61.53%
Perf. Since Inception
-64.68%

Technical Indicators

MA 38 Days
8.50$
MA 50 Days
8.10$
MA 200 Days
6.90$
RSI (14)
32.5
Volatility 30 Days
114.4%
Volatility 250 Days
65.8%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
303.0
PEG
P/B
0.9
P/S
0.5
EV/EBITDA
6.9
Price/FCF
5.4

Profitability

Gross Margin
69.0%
EBIT Margin
-7.9%
Net Margin
-7.1%
Return on Equity
-12.4%
Return on Assets
-3.2%

Balance Sheet & Safety

Equity Ratio
47.6%
Debt/Equity
0.8
warning zone
Altman Z″
-13.67
Piotroski
6 out of 9

Growth

Sales Growth Last Quarter
-2.50%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
-1.54%
Forward Sales Growth
1.25%
Forward EPS Growth
17.80%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
3
RS Rating
62
EPS Rating
42
Piotroski
6 out of 9
Fundamental Rating
D (41 out of 100)
warning zone
Altman Z″
-13.67

AI Rating

Uses AI

Teladoc Health setzt KI und maschinelles Lernen laut Geschäftsbericht 10-K für 2025 als Werkzeug ein — für interne Abläufe, die Effizienz der Behandlungsteams, die Zuordnung von Patient und Arzt sowie die Auswertungsplattform Pulse —, weist aber weder ein KI-Produkt noch einen KI-Umsatz gesondert aus: Der Umsatz wird nur nach Zugangsgebühren/Sonstiges und Regionen und in den zwei Segmenten Integrated Care und BetterHelp aufgeschlüsselt.

View the full file — quotes, sources, reviewed filings
„We use AI and machine learning to support internal operations, improve efficiency for care delivery teams, and enable certain member-facing features that provide educational resources, recommendations, or support."

Wir nutzen KI und maschinelles Lernen, um interne Abläufe zu unterstützen, die Effizienz der Behandlungsteams zu erhöhen und bestimmte an die Mitglieder gerichtete Funktionen zu ermöglichen, die Bildungsangebote, Empfehlungen oder Unterstützung bereitstellen.

10-K · 2026-02-26 · View SEC filing
„Our machine learning algorithms enable us to match members in the U.S. with available state-licensed, board-certified clinicians anytime, anywhere we operate, with 90% of Teladoc Health’s virtual urgent care visits occurring within thirty minutes of a member’s virtual visit request."

Unsere Algorithmen des maschinellen Lernens ermöglichen es uns, Mitglieder in den USA jederzeit und überall dort, wo wir tätig sind, mit verfügbaren staatlich zugelassenen, fachärztlich zertifizierten Behandlern zusammenzubringen; 90 Prozent der virtuellen Akutbesuche bei Teladoc Health finden innerhalb von dreißig Minuten nach der Anfrage eines Mitglieds statt.

10-K · 2026-02-26 · View SEC filing
„We offer a portfolio of services and solutions, bolstered by technology, artificial intelligence (“AI”), machine learning and human expertise to provide an effective care experience that people value and trust."

Wir bieten ein Portfolio von Dienstleistungen und Lösungen an, gestützt auf Technologie, Künstliche Intelligenz („AI“), maschinelles Lernen und menschliche Fachkompetenz, um ein wirksames Behandlungserlebnis zu bieten, das die Menschen schätzen und dem sie vertrauen.

10-K · 2026-02-26 · View SEC filing

Filings Reviewed: 10-Q 2026-04-30 · 10-K 2026-02-26 · 10-Q 2025-10-30 · 10-Q 2025-07-30 · 10-Q 2025-05-01 · 10-K 2025-02-27

Rated on July 29, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 6.70 $
Price Target (average) 7.76 $

The price target sits 15.8% above the current price.

Consensus
Hold
Analyst Ratings
24
Distribution of Recommendations
Strong Buy 3
Buy 2
Hold 19
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -0.74 -0.85 – -0.65 2,433 -12.3% 3
12/31/2027 -0.62 -0.68 – -0.55 2,432 16.5% 2

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

4. Aug 2026

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 640.5 $M Q4 2025: Q1 · 629.4 $M Q1 2025: Q2 · 631.9 $M Q2 2025: Q3 · 626.4 $M Q3 2025: Q4 · 642.3 $M Q4 2026: Q1 · 613.8 $M Q1 2026: Q2 · 606.9 $M Q2

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.28 641 -3.00 -7.60 86 56
2025: Q1 -0.53 629 -2.60 -14.80 16 -16
2025: Q2 -0.19 632 -1.60 -5.20 91 90
2025: Q3 -0.28 626 -2.20 -7.90 99 68
2025: Q4 -0.14 642 0.30 -3.90 88 85
2026: Q1 -0.36 614 -2.50 -10.40 10 8
2026: Q2 -0.21 -10.50 607 -4.00 -6.40 65 64
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 123 -63 -74 -1.75 -52 231 304
2017 233 -75 -107 -1.93 -34 559 824
2018 418 -71 -97 -1.47 -5 1,013 1,529
2019 553 -80 -99 -1.38 30 1,014 1,603
2020 1,094 -506 -485 -5.36 -54 15,884 17,755
2021 2,033 -266 -429 -2.73 194 16,046 17,735
2022 2,407 -13,198 -13,660 -84.60 189 2,308 4,701
2023 2,602 -249 -220 -1.34 350 2,326 4,392
2024 2,570 -1,021 -1,001 -5.87 294 1,491 3,517
2025 2,530 -263 -200 -1.14 294 1,386 3,101

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Assessment: Opportunities & Risks

Market position and reach

The world's largest virtual care provider: 101.2 million U.S. members in Integrated Care (March 31, 2026), 17.1 million visits in 2025, roughly 5,600 employees and a distribution network of employers, insurers and hospitals that cannot be recreated quickly.

Integrated Care core business

The larger segment grows and earns: $1,579.6 million of revenue and $239.2 million of segment adjusted EBITDA in 2025, rising from $50.4 million to $56.3 million in the first quarter of 2026. Consolidated gross margin stood at 69.3 percent as of July 28, 2026.

Revenue trend

Revenue has fallen for two straight years since the 2023 peak: $2,602.4 million (2023), $2,569.6 million (2024), $2,530.0 million (2025), plus another 2 percent decline to $613.8 million in the first quarter of 2026. The decline comes from BetterHelp, whose paying user count fell 9 percent to 0.361 million in that quarter; U.S. membership fell by 1.3 million to 101.2 million at the same time.

Balance sheet quality and goodwill

The 2025 annual report discloses $14.3 billion of cumulative goodwill impairment charges; Integrated Care goodwill stands at zero, which is why the Catapult Health ($59.1 million) and Telecare ($12.6 million) acquisitions were written off in the quarter they closed. The remaining $283.2 million hangs entirely on BetterHelp, and market capitalization stayed below book value during the first quarter of 2026.

Funding and the 2027 maturity

On June 1, 2027, $1,000.0 million of convertible notes fall due in cash — the roughly $242 conversion price makes a share conversion effectively impossible. Against that sit $750.7 million of cash (March 31, 2026), an undrawn $300.0 million revolver and roughly $166.9 million of annual free cash flow: covered on paper, but without a cushion.

Earnings quality

The $200.3 million net loss for 2025 sits against $294.4 million of operating cash flow; the gap comes mainly from $350.8 million of scheduled amortization of intangible assets. From that operating figure, however, $118.6 million of capitalized software development also has to come off — leaving roughly $166.9 million free.

Bottom Line

Teladoc Health is the purchase-price reflex in its purest form: of roughly $17.9 billion of shareholder capital paid in, $16,494.1 million now sits on the balance sheet as accumulated deficit, $14.3 billion of goodwill has been written back off by the company's own impairment tests, and inside the Integrated Care segment every acquisition is impaired on the day it closes. Underneath all of it, though, sits a real business: 101.2 million members, $2,530.0 million of revenue and $294.4 million of operating cash flow in 2025, out of which $550.6 million of maturing notes was retired without outside help. Three testable questions remain: a third year of revenue decline, the BetterHelp user curve, and the billion dollars due on June 1, 2027. Not investment advice.

Worth Noting:
  • Teladoc Health reached our research list through the list of most-discussed Reddit tickers in our scanner area (as of July 29, 2026), not through a momentum, quality or valuation screen. Those lists are recalculated daily.
  • Recency status: the most recent periodic report is the Form 10-Q for the quarter ended March 31, 2026, filed April 30, 2026. No further periodic report and no earnings release (8-K Item 2.02) followed through July 29, 2026; the only substantive filing after it was the Form 8-K of May 21, 2026 reporting the annual meeting results — all nine nominees elected, say-on-pay approved, Ernst & Young ratified as auditor for 2026. The most recent filing of any kind was a Form 4 insider report dated July 6, 2026. All market and valuation figures carry the July 28, 2026 data date.
  • Open personnel item: the finance seat has been vacant since Mala Murthy left on November 21, 2025; chief executive Charles Divita, III, signs both the Form 10-K for 2025 and the Form 10-Q for the quarter ended March 31, 2026 as principal financial officer. No 8-K under Item 5.02 announcing a successor had been filed through July 29, 2026.
  • Do not confuse the terms: “adjusted EBITDA” at Teladoc is a company-defined measure and is not comparable with similarly named metrics at other companies — the filing says so explicitly. Nor is operating cash flow the amount actually available: capitalized software development costs come off it ($118.6 million in 2025).

About the Company

Teladoc Health, Inc. bietet weltweit virtuelle Gesundheitsdienstleistungen an.

Employees4,648
HeadquartersNew York, NY
Address155 E 44th Street, 10017 New York, United States
Phone203 635 2002
Websiteteladochealth.com
IPO Date1. Jul 2015
ISINUS87918A1051

Management

Management
Name Title Birth Year
Charles Divita III, CPA CEO, Interim Principal Financial Officer & Director 1970
Adam Christian Vandervoort J.D. Chief Legal Officer & Secretary 1975
Carlos Nueno President of International 1974
Kelly M. Bliss President of U.S. Group Health 1975
George Byron Brooks BS EE, M.D. Co-Founder
Joseph Ronald Catapano Cpa Senior VP & Chief Accounting Officer 1969
Dave Ross Chief Technology Officer
Michael Minchak Vice President of Investor Relations
Laura Whipple Chief Communications & Brand Officer
Fernando Madeira President of BetterHelp 1970

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?